Achondrogenesis Market research report- Forecast till 2027

Achondrogenesis Market Information: by type (type IA (Houston-Harris type), type IB (Fraccaro type), type II (Langer-Saldino type)), Diagnosis (Molecular Genetic Testing, Biochemical Testing), End User (Hospitals & Clinics) - Forecast till 2027

ID: MRFR/MED/3247-HCR | February 2021 | Region: Global | 85 pages

Achondrogenesis Market Scenario


Achondrogenesis is a severe congential growth hormone deficiency that affects cartilage and bone development. This rare genetic disease is characterized by narrow chest, rounded abdomen, and extremely short limbs. There are majorly three types of achondrogenesis, type 1A, type 1B and type 2. Out of these three, type 1B is most severe and caused by mutations in the SLC26A2 gene. Achondrogenesis type 1B (ACG1B) is also known as Parenti-Fraccaro type. Achondrogenesis exhibits various symptoms such as, abdominal distention, flat face, anteverted nares, frontal bossing, lethal skeletal dysplasia, hydropsfetalis, abnormal enchondral ossification, and many others. According to the U.S National Library of Medicine, the incidence of 1A and 1B, whereas achondrogenesis type 2 occur in 1 in 40,000 to 60,000 newborns. The condition of achondrogenesis type 2 is mostly found in combination with hypochondrogenesis.


Appropriate treatment for the condition is unknown but to deal with the symptoms associated with achondrogenesis, palliative care is suggested by physicians. Genetic Counseling is also recommended to the people who have genetic disorders in their family history. Diagnosis or testing of achondrogenesis is based on histopathologic, clinical, and radiologic features. As per an article published in GeneReviews book, it is found that SLC26A2 is the only mutated gene known to cause ACG1B. Out of all the testing methods, molecular genetic testing is the most commonly used diagnosis for Achondrogenesis Type 1B. Molecular genetic testing method includes targeted mutation analysis, sequence analysis, and deletion/duplication analysis.


Notably, presence of mutated gene in the family history is the key factor driving the achondrogenesis market. As per the information suggested by National Center for Advancing Translational Sciences (NCATS), achondrogenesis type 1A and type 1B occur due to autosomal recessive inheritance which means each parent carry one copy of the mutated gene. However, it is also reported that achondrogenesis type 2 is an autosomal dominant disorder and typically found in people with no history of gene mutation in their family. Various other push factors such as, rise in facilities for patients affected by rare diseases, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the  achondrogenesis market.


Despite these drivers, there are some issues associated with achondrogenesis market. Challenges in research and development, and lack of skilled healthcare professionals in developing countries hinder the growth of achondrogenesis market to an extent.


It is estimated that achondrogenesis market is expected to grow at a CAGR 3.9% during the forecast period of 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Surgical equipment Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The achondrogenesis market is segmented on the basis of type, diagnosis, and end-users.


On the basis of type, achondrogenesis market is segmented into achondrogenesis type IA (Houston-Harris type), achondrogenesis type IB (Parenti-Fraccaro type), and achondrogenesis type II (Langer-Saldino type).


On the basis of diagnosis, achondrogenesis market is classified into physical examination, molecular genetic testing, and biochemical testing. Physical examination is further classified into X-ray, ultrasound, and others. Molecular genetic testing is also further segmented into Chorionic villus sampling (CVS), aminocentesis, and others.


On the basis of end-users, achondrogenesis market is segmented into hospital & clinics, diagnostic centers, research & academic institutes, and others.


Regional Analysis


The Americas dominate the achondrogenesis market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in achondrogenesis market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the achondrogenesis market in Europe region.


Asia Pacific is the fastest growing achondrogenesis market owing to the huge patient pool and developing healthcare technology.


Key Players


Some of key the players in the achondrogenesis market are Cook, Thermo Fisher Scientific, CooperSurgical Inc., Illumina, Inc., Siemens AG, FUJIFILM Holdings Corporation, Koninklijke, Philips N.V., Stryker, Toshiba Corporation, Invivoscribe, Abbott Molecular Inc., INVITROGEN CORPORATION, Roche Molecular Systems, Inc., and others.


Research Methodology
Achondrogenesis Market


Sources: Annual reports, Press release, White paper, and Company presentation


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   3.9% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cook, Thermo Fisher Scientific, CooperSurgical Inc., Illumina, Inc., Siemens AG, FUJIFILM Holdings Corporation, Koninklijke, Philips N.V., Stryker, Toshiba Corporation, Invivoscribe, Abbott Molecular Inc., INVITROGEN CORPORATION, Roche Molecular Systems, Inc., and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Presence of mutated gene in the family history
  • Increasing government assistance
  • Improvement in regulatory framework


  • BRIEF TOC

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope Of The Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power Of Suppliers

    5.1.2 Bargaining Power Of Buyers

    5.1.3 Threat Of New Entrants

    5.1.4 Threat Of Substitutes

    5.1.5 Intensity Of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Achondrogenesis Market, By Type

    6.1 Introduction

    6.2 Achondrogenesis Type IA (Houston-Harris Type)

    6.3 Achondrogenesis Type IB (Fraccaro Type)

    6.4 Achondrogenesis Type II (Langer-Saldino Type)

    Chapter 7. Global Achondrogenesis Market, By Diagnosis

    7.1 Introduction

    7.2 Physical Examination

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Molecular Genetic Testing

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Biochemical Testing

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Achondrogenesis Market, By End User

    8.1 Introduction

    8.2 Hospitals And Clinics

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Diagnostic Centers

    8.3.2 Market Estimates & Forecast, 2020 – 2027

    8.4 Research & Academic Institutes

    8.4.2 Market Estimates & Forecast, 2020 – 2027

    8.5 Others

    Chapter 9. Global Achondrogenesis Market, By Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.1 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest Of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic Of Korea

    9.4.6 Rest Of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest Of The Middle East & Africa

    Chapter 10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Cook

    11.1.1 Company Overview

    11.1.2 Types Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Thermo Fisher Scientific

    11.2.1 Company Overview

    11.2.2 Types Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 CooperSurgical Inc.

    11.3.1 Company Overview

    11.3.2 Types Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Siemens AG

    11.4.1 Company Overview

    11.4.2 Types/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Stryker

    11.5.1 Company Overview

    11.5.2 Types Overview

    11.5.3 Financial Overview

    11.5.4 Key Developments

    11.6 Toshiba Corporation

    11.6.1 Company Overview

    11.6.2 Types Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 FUJIFILM Holdings Corporation

    11.7.1 Overview

    11.7.2 Types Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs Of The Market

    12.2 Key Companies To Watch

    12.3 Prediction Of Achondrogenesis Industry

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Achondrogenesis Industry Synopsis, 2020 – 2027

    Table 2 Achondrogenesis Market Estimates And Forecast, 2020 – 2027, (USD Million)

    Table 3 Achondrogenesis Market By Region, 2020 – 2027, (USD Million)

    Table 4 Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 5 Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 6 Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 7 North America Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 8 North America Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 9 North America Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 10 US Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 11 US Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 12 US Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 13 Canada Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 14 Canada Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 15 Canada Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 16 South America Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 17 South America Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 18 South America Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 19 Europe Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 20 Europe Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 21 Europe Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 22 Western Europe Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 23 Western Europe Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 24 Western Europe Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 25 Eastern Europe Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 26 Eastern Europe Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 27 Eastern Europe Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 28 Asia Pacific Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 29 Asia Pacific Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 30 Asia Pacific Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    Table 31 Middle East & Africa Achondrogenesis Market By Types, 2020 – 2027, (USD Million)

    Table 32 Middle East & Africa Achondrogenesis Market By Condition, 2020 – 2027, (USD Million)

    Table 33 Middle East & Africa Achondrogenesis Market By End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation For Achondrogenesis Market

    Figure 3 Segmentation Market Dynamics For Achondrogenesis Market

    Figure 4 Global Achondrogenesis Market Share, By Types 2020

    Figure 5 Global Achondrogenesis Market Share, By Condition 2020

    Figure 6 Global Achondrogenesis Market Share, By End Users, 2020

    Figure 7 Global Achondrogenesis Market Share, By Region, 2020

    Figure 8 North America Achondrogenesis Market Share, By Country, 2020

    Figure 9 Europe Achondrogenesis Market Share, By Country, 2020

    Figure 10 Asia Pacific Achondrogenesis Market Share, By Country, 2020

    Figure 11 Middle East & Africa Achondrogenesis Market Share, By Country, 2020

    Figure 12 Global Achondrogenesis Market: Company Share Analysis, 2020 (%)

    Figure 13 Cook: Key Financials

    Figure 14 Cook: Segmental Revenue

    Figure 15 Cook: Geographical Revenue

    Figure 16 Thermo Fisher Scientific: Key Financials

    Figure 17 Thermo Fisher Scientific: Segmental Revenue

    Figure 18 Thermo Fisher Scientific: Geographical Revenue

    Figure 19 CooperSurgical Inc.: Key Financials

    Figure 20 CooperSurgical Inc.: Segmental Revenue

    Figure 21 CooperSurgical Inc.: Geographical Revenue

    Figure 22 Stryker: Key Financials

    Figure 23 Stryker: Segmental Revenue

    Figure 24 Stryker: Geographical Revenue

    Figure 25 Siemens AG: Key Financials

    Figure 26 Siemens AG: Segmental Revenue

    Figure 27 Siemens AG: Geographical Revenue

    Figure 28 Toshiba Corporation: Key Financials

    Figure 29 Toshiba Corporation: Segmental Revenue

    Figure 30 Toshiba Corporation: Geographical Revenue

    Figure 31 FUJIFILM Holdings Corporation: Key Financials

    Figure 32 FUJIFILM Holdings Corporation: Segmental Revenue

    Figure 33 FUJIFILM Holdings Corporation: Geographical Revenue